.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
Federal Trade Commission
Citi
Colorcon
Novartis
QuintilesIMS
Covington
Julphar
Express Scripts

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,893,074

« Back to Dashboard

Which drugs does patent 7,893,074 protect, and when does it expire?


Patent 7,893,074 protects ZYKADIA and is included in one NDA.

This patent has seventy-five patent family members in thirty-five countries.

Summary for Patent: 7,893,074

Title:2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Abstract: Novel pyrimidine derivatives of formula I ##STR00001## to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Inventor(s): Garcia-Echeverria; Carlos (Basel, CH), Kanazawa; Takanori (Tsukuba, JP), Kawahara; Eiji (Tsukuba, JP), Masuya; Keiichi (Tsukuba, JP), Matsuura; Naoko (Tsukuba, JP), Miyake; Takahiro (Tsukuba, JP), Ohmori; Osamu (Tsukuba, JP), Umemura; Ichiro (Tsukuba, JP), Steensma; Ruo (La Jolla, CA), Chopiuk; Greg (San Diego, CA), Jiang; Jiqing (San Diego, CA), Wan; Yongqin (Irvine, CA), Ding; Qiang (San Diego, CA), Zhang; Qiong (San Diego, CA), Gray; Nathanael Schiander (San Diego, CA), Karanewsky; Donald (Escondido, CA)
Assignee: Novartis AG (Basel, CH) IRM LLC (Hamilton, BM)
Application Number:10/568,367
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms CorpZYKADIAceritinibCAPSULE;ORAL205755-001Apr 29, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,893,074

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0319227.5Aug 15, 2003
United Kingdom0322370.8Sep 24, 2003
PCT Information
PCT FiledAugust 13, 2004PCT Application Number:PCT/EP2004/009099
PCT Publication Date:February 24, 2005PCT Publication Number: WO2005/016894

Non-Orange Book Patents for Patent: 7,893,074

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,964,5922,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders► Subscribe
8,263,590Pyrimidine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,893,074

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI378923► Subscribe
Taiwan200526598► Subscribe
TunisiaSN06052► Subscribe
TunisiaSN05225► Subscribe
Slovenia2287156► Subscribe
Slovenia2275413► Subscribe
Slovenia1660458► Subscribe
Singapore145749► Subscribe
Russian Federation2400477► Subscribe
Russian Federation2005131721► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
McKinsey
Fish and Richardson
Accenture
Fuji
McKesson
Baxter
Mallinckrodt
Covington
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot